Late non‐relapse mortality among adult autologous stem cell transplant recipients: a nation‐wide analysis of 1482 patients transplanted in 1990–2003
- 17 May 2006
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 77 (2) , 114-119
Abstract
Introduction: Data on the incidence and causes of late (>100 d) non‐relapse mortality (NRM) in autologous stem cell transplant (ASCT) recipients is limited.Patients and methods: We have analysed NRM in a cohort of 1482 adult patients who received ASCT in 1990–2003 in six Finnish transplant centres. The most common diagnoses included non‐Hodgkin's lymphoma (NHL) (n = 542), multiple myeloma (MM) (n = 528), breast cancer (n = 132); Hodgkin's lymphoma (HL) (n = 86) and chronic lymphocytic leukaemia (CLL) (n = 63).Results: Until September 2005, 646 patients (44%) have died. Late NRM was observed in 68 patients (4.6% of ASCT recipients; 11% of all deaths). There were 38 males and 30 females with a median age of 58 yr (20–69) at the time of ASCT. The median time to NRM was 27 months from ASCT (3–112). The risk of NRM was highest in patients with CLL (9.5%) and those with HL (8.1%) followed by MM and NHL (4.9% and 4.8%, respectively). The risk of late NRM was comparable in patients who received total body irradiation (TBI) and those who received chemotherapy‐only regimens (6.7% vs. 4.3%). Another malignancy was the most common cause of late NRM (24 patients, 35% of late NRM). Twelve patients (0.8% of ASCT recipients) have died due to secondary haematological malignancy. Altogether 22 patients (32% of late NRM) died from infectious causes.Conclusions: Malignancies and late infections are important causes of NRM after ASCT. These facts point out the importance of prolonged follow‐up in ASCT recipients.Keywords
This publication has 26 references indexed in Scilit:
- High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in VancouverBlood, 2005
- Increasing Incidence of Late Second Malignancies After Conditioning With Cyclophosphamide and Total-Body Irradiation and Autologous Bone Marrow Transplantation for Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2005
- Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMTBone Marrow Transplantation, 2005
- Secondary malignancies and quality of life after stem cell transplantationBone Marrow Transplantation, 2005
- Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysisBone Marrow Transplantation, 2003
- Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantationBone Marrow Transplantation, 2003
- Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphomaBone Marrow Transplantation, 2003
- Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation surveyBritish Journal of Haematology, 2002
- Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignanciesBone Marrow Transplantation, 2000
- Secondary Leukaemia and Myelodysplasia after Autografting for Lymphoma: Is the Transplant to Blame?Leukemia & Lymphoma, 2000